Everyone, my name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome the Beam Therapeutics management team here today. We're going to do fireside chat format. For those who are new to the story, maybe start off and give an intro to the company.
Sure. Thanks for having us. We're thrilled to be here. Beam, as a reminder, is a next-generation gene editing company. We have a particular technology called base editing, which enables us to do precise, targeted single-base changes in the genome within any cell that we can deliver to. Our portfolio currently consists of sickle cell disease, where we're doing ex vivo base-edited cells to treat severe sickle cell disease. That's risto-cel, which is on track for a BLA filing as soon as December of this year. Obviously very imminent. We just announced positive top-line data for that program. Very excited about that, and it's a milestone in the field. Longer term, of course, we also think about doing in vivo delivery for sickle cell, which is something that we are actively working on.
In the liver, we are focused on lipid nanoparticles, which are simple infusions of a couple of hours to get a one-time, durable, lifelong correction of a mutation. Our lead program there is BEAM-302 for alpha-1 antitrypsin deficiency. This is the first-ever program to correct a mutation in the body back to a normal sequence. This is partway now through a pivotal cohort for an accelerated approval.
We've recently guided that that is enrolling very swiftly. We will have the 50th dose in the first half of next year, and then follow that cohort for a year, and then that becomes a filing package for us. From there, we're expanding with this platform, which is now increasingly plug and play, looking at PKU as a next big indication, severe metabolic disorder, where we have a program that can treat up to 50% of PKU patients using three different editors.
We can go beyond that. We're going to be adding more editors over time, trying to reach as many of those patients as possible. Dosing will begin in the early part of 2027 for that program. We've recently disclosed data for BEAM-301 in an ultra-rare population targeting the R83C mutation for glycogen storage disease, which showed dramatic benefit for patients there to, again, correct a mutation and address this terrible disease. Significant momentum, I think, across the portfolio at this point, reaching multiple organs in the body. We see that expanding over time, and now an imminent transition to becoming a commercial-stage company with multiple assets in the portfolio.
Got it. It was a great intro. Maybe let's start off with the alpha-1 antitrypsin study. For that 50-patient study, having that enrollment timeline for first half of next year, it's nice having that defined. Maybe just talk about what you're seeing with enrollment and what the curve looks like getting there. Do you think it could be earlier in first half or potentially later?
I think too early to guide on the specifics. I think first half is good. Enrollment has been very swift. I think we've, as we've always said, we built this clinical network. We've been building relationships in the alpha-1 field for seven or eight years now. This has always been a big part of our strategy. We are in six countries. We have 15+ sites at this point open and enrolling, including numerous in the U.S. That has really driven the enrollment potential. I think the enthusiasm from patients, these are patients who generally, they are diagnosed, they're on augmentation therapy, which is a weekly infusion. They're very frustrated with that situation. They are eager to get a better option. The appeal of a one-time intervention that permanently gives them a correction to their underlying genetic defect seems to be very high.
We've been seeing that in terms of the enrollment. I think this is a big part of our first-in-class advantage, establishing a leadership position in this field with BEAM-302, and we intend to extend that over time.
Is there more you're seeing about the types of patients that you've enrolled into the study, and could you potentially over-enroll as well, go beyond the 50 patients?
Do you want to talk about the patients?
Yes. The patients are individuals that have demonstrated disease of the lung, and they may or may not have involvement of the liver. That is really the broad label that we intend to pursue in the pivotal trial. That is the vast majority of patients, more than 90% will be there. Obviously, the pivotal trial is, the accelerated approval trial is 50 patients, but we have also done a part A and B part of the study in which we looked at lung specifically, and then also patients with liver. We will continue actually to dose in those patients. In part, also gives us the opportunity to continue to generate data to look at many other aspects of the disease, including densitometry, of course, FEV1, the impact more broadly. We are doing BAL lavage sort of data just to look at the impact on the liver.
All of that data we feel will add to the dataset that obviously we are going to be proposing to the FDA. Importantly, it is also an opportunity for us to continue the journey with the patient population that are very interested in this product, and therefore continue that relationship even beyond the pivotal trial phase of it. To some extent, even from a competitive point of view, creating demand for our patients.
Got it. Makes sense. For the study, maybe just talk a little bit about screen failure rate and the most common reasons patients are excluded. Are you seeing any meaningful difference in enrollment productivity between the U.S. and ex-U.S.?
Screen failure rate has been low and predictable, I think, from part A, part B here. U.S., ex-U.S., actually, I'm not aware of any.
No, there hasn't been any real difference, frankly, in the recruitment rates that we've seen across the board. So it's been roughly the same, I would say.
Okay. At the ERS Congress earlier this year, you presented data from 11 patients for the part A and B dose escalation with mean steady state AAT around 14 micromolar. When could you do another data update, and would that update focus primarily on longer-term biomarker durability, or could you also include some of the CT densitometry data and liver biopsy data as well?
Yeah, just building on Pino's comments, I think all of that is coming. So we're doing all that work. I mean, that's part of what we want to do here is, of course, it's been an exciting story to talk about getting these patients to carrier levels of alpha-1, showing that it's 90%+ is all this corrected M. We've dramatically reduced Z. We've shown it's inducible.
These are all really exciting, and they form the basis for the accelerated approval pathway because we can clearly show the FDA this product is getting patients to what we believe is similar to a carrier, which would not have a disease, right? They're by definition not diseased, and so that should be sufficient for accelerated approval. But our job is then to push farther than that, and so we will definitely be giving updates from the phase I/II over time.
No guidance yet on when that will be, but you can expect periodic updates, and that will start to include things like liver biopsy for those patients with the liver disease. In the lung, we will be taking bronchoscopies to measure BAL fluid and look at the levels of inflammation in the lung. That is a direct measure of disease process. Then longer term, absolutely, we are measuring CT densitometry, which shows the tissue destruction of the disease over time. You want to see that slow down. FEV1, patient-reported outcomes, we are measuring all of that.
Got it. The registrational cohort is 12 months. Would you have some of those data measures before that readout? Would that be something that you share with the public, or would you save that for the FDA discussions first?
I would say, for the pivotal cohort, the 50 patients, we are not planning to do any interim readout or disclosure. That is actually in part for ensuring that the data integrity is there. There is a typically, you do not want to dip into that data because it compromises, frankly, the statistical aspect of it. But we can use, obviously, the additional cohorts as a way to provide some updates on that. You will see the good news that you will see, at least up until now, the data is very stable, and what you have seen already is what we expect, frankly, to see in the broader population moving forward.
Got it. Your phase I/II protocol also captures COPD exacerbations by severity and patient-reported outcomes. Maybe just talk about the importance of those data.
Yeah, I mean, I think all of this is measuring what we believe will be a stabilization of the disease. Obviously, to a degree, some of these patients have damage that will be irreversible. I mean, that's the unfortunate fact of this disease. We don't believe lung tissue can come back, but we should see stabilization. We want to see stopping progression, slowing progression. Liver is a little different, actually. I mean, I think with liver, it's a fairly regenerative organ, so we have some hope that once you stop the production of Z at that high level, we should see the liver be able to turn over over time and actually recover. This is a drug that will be of interest across the spectrum of the disease.
Patients who are very severe at the end of life, they're going to have a lot of liver burden and lung burden. So a one-time intervention that can potentially address both problems is, of course, of interest to them. At the same time, young patients, earlier patients who are just beginning their disease journey, this is prevention, right? This is going to stop them from picking up all the damage that all these other patients have had to have. There's a lot of interest in pushing it to that direction as well. So I think we have something to provide for the full spectrum of disease patients.
Got it. Makes sense. Your competitor, one of your competitors, YolTech/Serapha recently reported liver biopsy data from a single patient and kind of showed a good case study work up there. Given that you're still awaiting approximately six months follow-up from patients dosed over the summer, could we see similar liver biopsy analyses from part B in 2027 and potentially across both the 30 mg and 60 mg cohorts doses?
Yeah, I think, again, we don't do the single patient case study, but we'll definitely have a data set that I think you can expect. We haven't guided on exactly when, but it's reasonable to expect the next set of kind of evolution of our data set will include things like liver biopsy, BAL data in the lung, et cetera, and then over time, longer term outcomes for functional readouts.
Got it. You have shown that BEAM-302 can actually work along with an acute phase response. Have you seen more examples of that, and can you comment on that?
We cannot comment on what we are seeing until we give data. I think obviously it was very gratifying to see the upregulation of the gene. This is because we are fixing the gene in its normal location, so it has its normal on-off switch. This is a big part of how this gene works, and so by correcting the gene in its normal place, when you get sick, your body wants to create more alpha-1 protein. That is how you get extra protection for your lungs. Ours will do that, and we have seen that. So we are in the kind of mid-teens as a baseline, but when you are sick, we go to 25. So we have one very clear case study of that where there was an upper respiratory infection.
We will be tracking this over time, and as we pick up additional cases, we expect that to show the same effect. That is an important feature that people need to process, which is that this is different than augmentation, right? We have lived with augmentation where you are going to dose and you have to worry about what your trough level is because that is all you are going to get, right? It is never going to go up until you redose.
When you are sick, that is the maximum protection you have. With augmentation, you have to think about the number as the protective floor. For correction, that is not the case. Correction, like a carrier, we are going to get people to the teens, but when they are sick, they will be in the 20s. So it is a different shaped curve because it is endogenously producing the protein when you need it.
Yeah. I think it is a key benefit of the editing approach that may not be fully appreciated. With your confirmatory study, maybe talk about that. As far as our understanding goes, it only needs to be open for enrollment at BLA submission. When do you plan to reengage FDA to finalize the confirmatory design and endpoints? There is another phase III that is reading out the SPARTA study, which will have CT densitometry data expected potentially by the end of this year. Are you waiting for that to make decisions around your confirmatory study?
Yeah. As you mentioned, we have a little bit of time until all of that needs to be confirmed, therefore, we want to create the opportunity for us to do the best design that we think is possible. Certainly, CT densitometry would be our favorite endpoint. We think that it's actually the most sensitive assay to detect the progressive damage that occurs in these patients of the lung. The SPARTA data is due to come out, as we understand, by the end of this year, then maybe provide some further instruction as to whether CT densitometry can be considered a meaningful pivotal endpoint as part of that. The reality, though, is that we think that the confirmatory trial, first of all, is not on the critical path for the product to be launched and taken up.
We have very strong confidence and feedback from our commercial assessment that the accelerated approval path will actually be sufficient for the product to be taken up and actually reimbursed. That's because the disease is so well understood and the biomarkers are so well predictive, if you will, of the disease. Also, the other thing I would say is that even though if the CT densitometry may not be the endpoint that the FDA may choose at the end, although I guess the official position from them is that they're evaluating that, I think there is still the possibility of doing a confirmatory trial anyway, even with FEV1 and St. George's Respiratory Questionnaire. It's just a slightly different design. It may take a little bit longer, but it's not critical path.
Makes sense. Wave disclosed their registrational study design, or some aspects of it. I guess, does that give you more confidence that the 50 patients with longer-term follow-up could be sufficient for confirmatory data?
It may be possible, for sure, but the reality, I don't know that Wave has disclosed too many details about what exactly that looks like. So I think it remains to be seen. I'm confident in the interactions that we've had with the FDA and the feedback that we got. We have the opportunity, obviously, to interact. We have an RMAT designation for this program, so we can engage with the FDA on a more regular basis, and we'll continue to do so.
Makes sense. If FDA became open to accelerated approval based on six months' data with the AAT biomarkers, would you amend the protocol to allow an earlier analysis, given your current agreement to analyze the data at 12 months? Have you raised this with FDA previously, and what was their feedback?
So obviously, the official feedback from the FDA so far is that they want to see 12 months of follow-up, and that's obviously how we are doing that. But as I said, given the RMAT designation, we reserve the right, obviously, to interact with the FDA on any given basis. If we have data which is as robust and strong as we expect it to be on the basis of the data, we'll obviously take the opportunity to engage with them and see where we can go. But right now, the guidance is based on the feedback that we received, which is 12 months of follow-up.
Makes sense. Can you comment more on just, I guess, what would the strength of the data be? What would that bar be for you to go back to FDA?
Yeah. If you think about it, this is a disease where there is a certain degree of variability in the levels. Even on a given patient, you will see some fluctuations on the steady state level of that. So really, what the FDA, I think, is concerned about is to ensure that there is a real strong difference between your baseline and eventually the steady state at which these patients will be. But if you see the data that we've already disclosed, even in the earlier cohorts, obviously those are lower doses, but you will see now we've got follow-up all the way to 24 months in some of these individuals, and you will see there is really no variability fundamentally.
Yeah.
The baseline is very, very steady. If you can demonstrate a very steady state benefit over a certain period of time, then there may be an opportunity for us to reengage with them. This is something that we can't plan on it right now. I think our plan is basically to generate the robust dataset in 12 months, and we shall see.
Got it. Yeah, that makes sense. Maybe talk about the competitive landscape a little bit. With Serapha, they're preparing to start a U.S. phase II/III study by the end of this year, early next year. Prime and CRISPR and other competitors are advancing in alpha-1. How do you think about maintaining your first mover advantage as these programs go forward?
Well, I think the first mover advantage is locked in at this point. I mean, we're multiple years ahead. We've treated, I think disclosed at least 30. Of course, we've treated much of cohort C now is in process, which will add another 50 on top of that. I think those competitors have at most treated a couple patients in two cases and none in the other cases. So, I think we've got a big lead. I think people will want to look at the levels that are being produced by patients treated with these other disease agents. I think that by and large, you're going to see minimal differentiation. There's a convergence, I think, of that data. I think it is all about first-in-class advantage, and I think we're well positioned for that.
For us, it's all about speed and establishing that benchmark within the market, getting the relationships with payers and sites up and running. This is an indication where first mover matters because it's highly scalable, even more than a sickle cell, that there's no hospital capacity limitation to treating as many patients as we can. So I think there's every ability with an LNP drug like this to treat a lot of patients on market once we get there. Then our commitment to the field will be a very long-term one.
Makes sense. Maybe briefly, just recognizing the sensitivity around ongoing litigation, can you provide any perspective on the expected procedural timeline for the YolTech/Serapha lawsuit, including key milestones investors should know?
No, I can't. I won't speak to any lawsuits.
Okay.
I think at the end of the day, Beam feels very strongly about protecting our innovation, protecting what we've invested in. That's critical. So we'll continue to do that. Our primary focus is creating an amazing set of medicines for patients and moving them as quickly as we can to market, which we will do.
Got it. At the beginning, you highlighted the risto-cel data that you recently reported, and you're going to have data at ASH as well. Can you walk us through what remains to finalize the clinical and other sections for the BLA, and what needs to happen operationally to submit before end of this year, if that's possible? Given the tight timeline, is there a realistic possibility of that happening?
Yeah. Maybe if I could sort of open with one comment on risto-cel, which I think is quite important, and then I would invite my colleagues to expand on sort of the pathway to market. There is a pretty important update this week, actually, on sort of the sickle market. This is an announcement from Genetix, which is marketing LYFGENIA, about their progress commercially. One of the big questions we have gotten a lot on risto-cel is, well, is there really a market there? And the only launch that has been in view so far has been the CASGEVY launch, because that is obviously associated with public companies, and LYFGENIA has been taken private.
But we now can see from both recent CASGEVY updates and now from this new update from LYFGENIA that, in fact, the total category sales this year for the two products is going to be north of $700 million. Okay, so that is a very, I think, significant update to what we have understood so far. And obviously, a big part of that has been LYFGENIA. So LYFGENIA is guiding to $500 million this year in the U.S. for that product.
So this is a really important visibility, I think, into what we have always believed was the case, which was there is very strong patient demand in this category. The hospitals are ready to go. They are eager to do it. The payment and the pricing is working. Medicaid is supportive. There has not been any rejections. It really has been just, it is an ex vivo process. You have to stand it up.
I think delivering on manufacturing is a challenge here, and that has been something that is a work in progress. But nonetheless, in sort of the second full year of really booking sales, we are already at that rate. And if you look at the new starts that those companies are reporting for this year, which would project to revenues next year, it is going to be even higher still. So I would project this will be a billion-dollar-plus category starting next year. Into that, we will bring risto-cel as the third agent, which we continue to feel is differentiated on its hematology outcomes, its time to engraftment performance, and its manufacturing with our internal manufacturing facility. So, we are quite excited about what that product can do to bring an important new option to patients.
So maybe just with that preamble that I wanted to make sure we covered, because I think it is an important update, maybe Pino can talk a little bit about path to market.
Yeah, certainly. As far as general remaining steps, fundamentally, we are finalizing the writing of the full BLA, so we remain on track, we believe, for filing in December of this year. Hopefully, things will continue to do. How quickly the review depends on whether the FDA will give us Priority Review. If that's Priority Review, probably sort of third quarter of next year would be when we could expect for it to be approved. If not, standard review will be 12 months, so it will be December of 2027.
Got it.
I wonder if I could also maybe ask Sravan just to comment a little bit again on what we're learning about what it's going to take to succeed in the market and what it was required to commercialize.
Along with the Genetix update, I think one of the things that was really exciting to see was profitability associated with their profile. Given the fact that majority of these patients are clustered in large centers across the U.S., we think that the footprint here for commercial setting is, or field force, is modest and right-sized for that. We've begun the work already of beginning the process of onboarding patient journey tracking and systems and coordinating with the hospitals already. The benefit of being third in this market is actually a lot of the class awareness has already started, so we're not coming in and writing de novo agreements with hospital systems or having to prevail on the benefit of this type of therapy.
We come in with our best-in-class clinical profile, and we are able to come in with first, taking these patients to a point where they are essentially like trait patients, where we are 60% fetal hemoglobin, 40% sickle, which the others don't. Faster time to engraftment by several days, which is really important. Then lastly, full resolution of anemia, which the others don't as well. So bringing the best-in-class clinical profile to a market that is well-established and growing, we are pretty excited about the opportunity.
Yeah, makes sense. Genetix seems like they are doing really well and helping validate the opportunity. I definitely agree with that. As far as differentiation goes, maybe talk about just cell mobilizations, how many you anticipate there, and just the time.
Yeah, in terms of mobilization, if you look at just the data we generated during the BEACON trial, our median was single round mobilization. That is very meaningful for the patient because as you know, it is more of a complicated situation. Obviously, they need a central vein, so it is part of that. So we think in part maybe contributing to that is the opportunity that base editing actually provides by not making double-stranded breaks. We seem to generate basically healthier cells, and also with our fully automated manufacturing process, we can have a more efficient and we need less cells basically to make the dose. That is definitely what we would expect to see continued when we launch with this program, and that is meaningful.
Got it. We did not talk about PKU and GSD1a. Maybe just in closing, if you want to highlight anything else from the pipeline and key events ahead that people should be focused on.
Maybe just the one thing to say on PKU and GSD, which we covered in our ESGCT conference call around the GSD data, so it is worth highlighting that for you if you have not watched it. I think there is a lot covered there. The most important thing is this evolution of the FDA and the way that they are changing guidelines to enable us to treat patients faster. In editing with sickle cell and with alpha-1, the same editor treats all the patients, but in PKU and GSD, you have the rainbow of different mutations.
The FDA has now made rules where we can basically package multiple editors, multiple guide RNAs for different mutations into a single product for the same disease. This has never been done in medicine, and it is really revolutionary. With PKU, we already have a product that includes three different editors for three different mutations.
Together, that will cover about half of all PKU patients. We have the ability to go further with this latest guidance to add more editors into that package, not even with clinical data. It just may be with in vitro testing, so long as you are showing that these editors are going to perform the same way as the clinically tested editors. We think that that will enable not just in PKU, of course, to treat many patients, but to create a series of products to really address a much larger total addressable market, which is really all of liver genetic disease effectively. Then, of course, as we work on delivery, we hope to do this in other organs as well over time.
Got it. John, Pino, Sravan, thanks so much for joining us today.
Thank you.
Thank you.